Abdominal wall perforation in a patient with recurrent epithelial ovarian cancer after bevacizumab treatment
Bowel perforation is a rare but well-described complication of bevacizumab, a VEGF monoclonal antibody. However, bevacizumab associated abdominal wall perforation is a more serious complication. In here, a patient with recurrent epithelial ovarian cancer developing both bowel and abdominal wall perf...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Turkiye Klinikleri
2016-08-01
|
| Series: | Journal of Oncological Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336416300036 |